Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

vibegron

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Objective To evaluate the efficacy of a novel and selective β3‐adrenoreceptor agonist vibegron on urgency urinary incontinence… Expand
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2020
2020
PURPOSE To assess efficacy, safety, and tolerability of vibegron, a novel, potent, highly selective β3-adrenoceptor agonist… Expand
Is this relevant?
2019
2019
BACKGROUND Antimuscarinics have shown modest efficacy with unwanted side effects in patients with overactive bladder (OAB… Expand
Is this relevant?
2019
2019
Objectives To investigate the efficacy of vibegron on nocturia in patients with overactive bladder. Methods Among the Japanese… Expand
  • table 1
  • figure 1
  • figure 4
  • figure 6
Is this relevant?
2018
2018
BACKGROUND Vibegron is a novel, potent, and selective β3-adrenoreceptor agonist for the treatment of patients with overactive… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2018
2018
Vibegron is a selective beta 3 adrenergic receptor (β3AR) agonist that is being developed in Japan jointly by Kyorin… Expand
Is this relevant?
2018
2018
Described here is an efficient stereoselective synthesis of vibegron enabled by an enzymatic dynamic kinetic reduction that… Expand
Is this relevant?
2018
2018
OBJECTIVES To evaluate the long-term safety and efficacy of vibegron 50 mg and 100 mg, a novel β3 -adrenoreceptor agonist, in… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2017
2017
Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists… Expand
  • table 1
  • table 3
  • table 4
Is this relevant?
2016
2016
The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?